November 4, 2011 – PhysioSonics announced that it received a $2.5 million grant from the Telemedicine and Advanced Technology Research Center (TATRC). TATRC is an organization within the headquarters of the U.S. Army Medical Research and Materiel Command, located at Fort Detrick, Maryland. With this grant, PhysioSonics will optimize its proprietary cerebral blood-flow monitor to detect vasospasm.  Following a successful launch in the civilian healthcare market, the military will test the blood-flow monitor with the goal of deploying it at military facilities that care for soldiers with traumatic brain injuries (TBI).  

November 4, 2011 – W. L. Gore & Associates announced that Royal Sussex County Hospital in Brighton, United Kingdom, is the first medical center in the United Kingdom to enroll a patient in the Gore REDUCE clinical study. The study is a U.S. Food and Drug Administration (FDA)-approved prospective, randomized, multi-center, international trial designed to demonstrate safety and effectiveness of the Gore HELEX septal occluder for patent foramen ovale (PFO) closure in patients with a history of cryptogenic stroke or imaging-confirmed transient ischemic attack (TIA). The unique study includes up to fifty investigational sites in the United States and Europe. This patient enrollment was achieved by the site’s study investigator, David Hildick-Smith, M.D., director of cardiac research unit, Brighton and Sussex University Hospitals.